OnabotulinumtoxinA (BOTOX®, Allergan plc, Dublin, Ireland) is approved for the preventive treatment of headaches in adult patients with chronic migraine (CM) in Australia by the country’s reimbursement mechanism for medicines, the Pharmaceutical Benefits Scheme (PBS). To our knowledge, this study represents the first focused report evaluating real-world evidence of onabotulinumtoxinA treatment via the PBS in Australian clinics
Once again the Australian initiative known as the 'Migraine World Summit' is about to make their free lecture series available to all migraine sufferers. It is an incredible evidence-based resource headlined by speakers that typically present at international headache conferences targeted at headache specialists. The talks are not 'dumbed-down' versions of medical talks, rather they present the same information in a more digestible interview-style format. I highly recommend them for all patients and often watch them myself to help improve the way I communicate with patients, both during individual consultations and public education seminars.
This is an excellent online series of lectures and associated resources. It was initiated by a group of very savvy migraine patients and contains lectures by the same experts that talk at medical conferences around the world. It is free during the annual week-long summit and thereafter there is a small access fee which is donated to research.